Woburn, MA (PRWEB) April 25, 2013
PathoGenetix, Inc. has signed a collaborative agreement with the U.S. Food and Drug Administration (FDA) to evaluate the company’s proprietary bacterial identification technology for use in FDA foodborne illness outbreak investigation and response. The Genome Sequence Scanning™ (GSS™) system provides pathogen serotyping and strain typing, directly from complex mixtures such as enriched food and clinical samples, in just five hours.
Identifying the specific pathogen causing a foodborne illness outbreak is a critical step in defining the extent of the outbreak, determining the food involved, finding the source of the contamination and defining the scope of a product recall. The ability of GSS™ to derive useful data directly from a complex mixture and to shorten the time for pathogen subtyping, may allow for quicker decisions affecting public health.
“We are very pleased to collaborate with FDA to demonstrate the value of GSS™ in FDA efforts to ensure safe food and improve public health,” said PathoGenetix CEO Ann Merrifield. “Reducing the time involved in foodborne outbreak investigations means quicker response time, and that means fewer illnesses and deaths from contaminated food.”
The bacterial strain information provided by GSS™ is comparable to pulsed field gel electrophoresis (PFGE), the current gold standard for pathogen typing in foodborne illness outbreak investigation and response.
The increased automation in preparation, measurement and analysis in the GSS™ system has the potential to reduce the need for advanced laboratory and analysis skills in hospital and p
Copyright©2012 Vocus, Inc.
All rights reserved